Big Money Sentiment increased to 1.1 in Q4 2018. It has change of 0.30, from 2018Q3’s 0.8. The ratio is positive due to Supernus Pharmaceuticals, Inc. positioning: 29 sold and 76 reduced. 34 funds amassed positions and 82 increased positions. Investors holded 48.83 million in 2018Q3 but now own 49.20 million shares or 0.77% more.
Renaissance Limited Liability Corp has 0.02% invested in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) for 10,645 shs. Neumeier Poma Counsel Ltd owns 494,331 shs for 1.56% of their capital. Carroll Associate invested in 0% or 150 shs. 39,352 are held by Gotham Asset Management Limited Liability Company. Financial Bank Of Montreal Can holds 41,884 shs. 195,884 are held by State Common Retirement Fund. Swiss Retail Bank invested in 92,300 shs or 0% of the stock. Massmutual Tru Fsb Adv has 35 shs for 0% of their capital. 5,433 were accumulated by Ls Investment Advsr Ltd Liability Corporation. California Pub Employees Retirement System invested in 75,571 shs. 15,649 are held by Juncture Wealth Strategies Ltd Liability Company. Citadel Advsr Limited stated it has 74,992 shs. Cs Mckee L P holds 0.12% of its capital in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) for 37,550 shs. Hbk Invests L P has 25,500 shs. Smith Asset Mngmt Group Lp holds 16,577 shs or 0.02% of its capital.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) decreased to $37.39. On Apr, 12 the move was reported by Barchart.com. The company has $1.96B MC. The valuation of NASDAQ:SUPN can change by $58.68 million if our $36.27 target is touched.

On May, 14. Investors wait Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) to announce its quarterly earnings, according to Zacks. The earnings per share diference is $0.05 or 10.20 % down from last years number. Previous year: $0.49; Analysts forcast: $0.44. SUPN’s profit could reach $23.02 million if the current earnings per share of $0.44 is accurate. Wall Street predicts -8.33 % negative EPS growth as of May, 14.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Ratings Coverage

In total 4 analysts cover Supernus Pharmaceuticals (NASDAQ:SUPN). “Buy” rating has 4, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 9 are the (NASDAQ:SUPN)’s analyst reports since November 12, 2018 according to StockzIntelligence Inc. On Monday, March 4 FBR Capital maintained Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) rating. FBR Capital has “Buy” rating and $65 target. In Monday, December 17 report Mizuho maintained the stock with “Buy” rating. On Monday, February 25 FBR Capital maintained Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) with “Buy” rating. The company rating was maintained by FBR Capital on Monday, November 12. On Wednesday, February 27 Cantor Fitzgerald maintained Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) rating. Cantor Fitzgerald has “Buy” rating and $57 target. On Wednesday, February 27 Mizuho maintained Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) with “Buy” rating.

For more Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) news brought out briefly go to: Nasdaq.com, Seekingalpha.com, Seekingalpha.com, Globenewswire.com or Globenewswire.com. The titles are as follows: “First Week of SUPN May 17th Options Trading – Nasdaq” brought out on March 21, 2019, “Supernus Succeeds In Phase 3, But Could Face An Uphill Battle – Seeking Alpha” on December 07, 2018, “Superlative Quarter For Supernus – Seeking Alpha” with a publish date: February 28, 2019, “Supernus to Present at the 2019 Cowen Health Care Conference – GlobeNewswire” and the last “Supernus to Host Fourth Quarter and Full Year 2018 Earnings Conference Call – GlobeNewswire” with publication date: February 12, 2019.

Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States.The firm is valued at $1.96 billion. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.The P/E ratio is 18.24. The company's product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder ; and SPN-812, a viloxazine hydrochloride, which is in Phase III clinical trial that is used for the treatment of ADHD.